The short version
- Why people research itAppetite suppression, fat loss and glucose control (GLP-1).
- What the evidence isAmong the best-evidenced drugs in modern medicine.
- What to watchSevere upper belly pain that bores to the back while using Semaglutide.
How Semaglutide works
GLP-1 receptor agonist — appetite regulation, slowed gastric emptying, glucose-dependent insulin release.
Semaglutide is not a hormone. And almost everything interesting about it is in the three modifications that buy that week.
Modification one: the residue that blocks the protease. Native GLP-1 is destroyed by dipeptidyl peptidase-4, which clips the first two residues off the N-terminus. Semaglutide substitutes alpha-aminoisobutyric acid — a non-standard, doubly methylated amino acid — at position 8, the residue DPP-4 has to reach past.
- Injectable
Research on Semaglutide6 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
Among the best-evidenced drugs in modern medicine. FDA-approved for type 2 diabetes (Ozempic/Rybelsus) and obesity (Wegovy) on the back of the SUSTAIN and STEP programs — STEP 1 produced ~15% mean body-weight loss over 68 weeks against ~2.4% on placebo.
SELECT then showed a 20% reduction in major cardiovascular events in people with obesity and established cardiovascular disease but without diabetes. That is an outcome trial, not a surrogate marker, and it is the result that moved this from a weight drug to a cardiometabolic one.
Correlative data
Enormous real-world exposure, and what it added to the trials is the tail the trials were too short and too supervised to show: rapid weight regain on discontinuation, disproportionate lean-mass loss without resistance training and adequate protein, and gastroparesis reports that led to a label change.
Compounded and gray-market semaglutide is a different product from a different supply chain. And salt forms (semaglutide sodium/acetate) are not the studied molecule.
How the mechanism reads
A GLP-1 receptor agonist with a fatty-acid chain that binds albumin, giving a ~1-week half-life. It slows gastric emptying, suppresses appetite centrally and improves glucose-dependent insulin secretion.
MechanisticThe mechanism predicts the side-effect profile precisely: nausea and early satiety are the gastric-emptying effect, not an intolerance. It also predicts the muscle-loss problem — appetite suppression is indiscriminate about which tissue the deficit comes from.
Mechanistic
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021 · PMID 33567185
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine 2023 · PMID 37952131
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine 2022 · PMID 36216945
- Colhoun HM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature Medicine 2024 · PMID 38796653
- Kushner RF, et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring) 2025 · PMID 39948761
- U.S. Food and Drug Administration. WEGOVY (semaglutide) injection, for subcutaneous use — full prescribing information, including the boxed warning for thyroid C-cell tumors. DailyMed, U.S. National Library of Medicine; label revised 2026
Semaglutide safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Medullary thyroid cancer or MEN2 in the family: semaglutide carries the boxed rodent C-cell warning.
- Diabetic retinopathy: very fast glucose lowering has been linked to short-term worsening of eye disease.
- Pancreatitis history or severe gastroparesis.
- Insulin or sulfonylurea use, or type 1 diabetes.
- Pregnancy: it is stopped well before trying to conceive.
What’s expected
- Lower appetite and quicker fullness from GLP-1 action and slowed stomach emptying.
- Nausea, constipation or loose stools, mostly early.
- A few beats faster resting pulse.
- Some muscle lost with weight, so strength training matters.
Watch for
- Severe upper belly pain that bores to the back while using Semaglutide.
- Right-sided pain with fever or yellow eyes while using Semaglutide.
- Vision change while using Semaglutide.
- Vomiting with dizziness and low urine.
Labs that tell you it’s working
- HbA1c (Hemoglobin A1c)
- Lipase
- Comprehensive Metabolic Panel (CMP)
- Cystatin C with eGFR
Long-acting GLP-1 receptor agonist; large outcome trials reflect years of use, and class effects fall on pancreas, gut and eyes. PMID 33567185 PMID 37952131
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel, explained
Semaglutide FAQ4 common questions
- Is Semaglutide approved for human use?
- Semaglutide is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is Semaglutide researched for?
- Appetite suppression, fat loss and glucose control (GLP-1).
- Which labs show whether it's doing anything?
- HbA1c; Lipase; Comprehensive Metabolic Panel; Cystatin C with eGFR: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Semaglutide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




